A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BioNTech SE
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
University of Southern California